PRECISION 1: Nab-Sirolimus for the Treatment of Patients With TSC1/2 Mutant Advanced or Metastatic Solid Tumor
Condition: Solid Tumors
Sponsor: Aadi Bioscience, Inc.
TSC-007: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
mTOR inhibitor nab-sirolimus
For patients with an advanced or metastatic TSC1/2 mutant solid tumor that have been treated with or are ineligible for all available standard of care therapies.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.